This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khuri, F. R. Articles by Hong, W. K. Search for Related Content PubMed PubMed Citation Articles by Khuri, F. R. Articles by Hong, W. K.

The Impact of Smoking Status, Disease Stage, and Index Tumor Site on Second Primary Tumor Incidence and Tumor Recurrence in the Head and Neck Retinoid Chemoprevention Trial¹

University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [F. R. K., E. S. K., J. J. L., R. J. W., S. E. B., S. M. L., R. M. C., B. W., H. G., W. K. H.]; Radiation Therapy Oncology Group, Philadelphia, Pennsylvania 19106 [F. R. K., K. K. F., J. S. C., E. E. V., T. P., H. G., W. K. H.]; Southwest Oncology Group, San Antonio, Texas 78205 [S. M. L.]; Cancer and Leukemia Group B, Boston, Massachusetts 02116 [E. E. V.]; and Community Clinical Oncology Programs, Houston, Texas 77030 [R. J. W., B. W.]

Second primary tumors (SPTs) develop at an annual rate of 3–7% in patients with head and neck squamous cell cancer (HNSCC). In a previous Phase III study, we observed that high doses of 13-cis-retinoic acid reduced the SPT rate in this disease. In 1991, we launched an intergroup, placebo-controlled, double-blind study to evaluate the efficacy of low-dose 13-cis-retinoic acid in the prevention of SPTs in patients with stage I or II squamous cell carcinoma of the larynx, oral cavity, or pharynx who had been previously successfully treated with surgery, radiotherapy, or both, and whose diagnoses had been established within 36 months of study entry. As of September 16, 1999, the Retinoid Head and Neck Second Primary (HNSP) Trial had completed accrual with 1384 registered patients and 1191 patients randomized and eligible. All of the patients were followed for survival, SPT development, and index cancer recurrence. Smoking status was assessed at study entry and during study. Smoking cessation was confirmed biochemically by measurement of serum cotinine levels. The annual rate of SPT development was analyzed in terms of smoking status and tumor stage. As of May 1, 2000, SPTs have developed in 172 patients. Of these, 121 (70.3%) were tobacco-related SPTs, including 113 in the aerodigestive tract (57 lung SPTs, 50 HNSCC SPTs, and 6 esophageal SPTs) and 8 bladder SPTs. The remaining 51 cases included 23 prostate adenocarcinomas, 8 gastrointestinal malignancies, 6 breast cancers, 3 melanomas, and 11 other cancers. The annual rate of SPT development observed in our study has been 5.1%. SPT development related to smoking status was marginally significant (active versus never, 5.7% versus 3.5%; P = 0.053). Significantly different smoking-related SPT development rates were observed in current, former, and never smokers (annual rate = 4.2%, 3.2%, and 1.9%, respectively, overall P = 0.034; current versus never smokers, P = 0.018). Stage II HNSCC had a higher overall annual rate of SPT development (6.4%) than did stage I disease (4.3%; P = 0.004). When evaluating the development of smoking-related SPTs, stage was also highly significant (4.8% for stage II versus 2.7% for stage I; P = 0.001). Smoking-related SPT incidence was significant for site as well (larynx versus oral cavity, P = 0.015; larynx versus pharynx, P = 0.011). Primary tumors recurred at an annual rate of 2.8% in a total of 97 patients. The rate of recurrence was higher in patients with stage II disease (4.1% versus 2.2%, P = 0.004) as well as oral cavity site when compared with larynx (P = 0.002). This is the first large-scale prospective chemoprevention study evaluating smoking status and its impact on SPT development and recurrence rate in HNSCC. The results indicate significantly higher SPT rates in active smokers versus never smokers and significantly higher smoking-related SPT rates in active smokers versus never smokers, with intermediate rates for former smokers.

This article has been cited by other articles:

				X. Wu, J. Gu, Q. Dong, M. Huang, K.-A. Do, W. K. Hong, and M. R. Spitz Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7194 - 7201. [Abstract] [Full Text] [PDF]

				V. G. Vogel Identifying and Screening Patients at Risk of Second Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2027 - 2032. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				S. J. Wong, M. Machtay, and Y. Li Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy, or Chemotherapy Alone? J. Clin. Oncol., June 10, 2006; 24(17): 2653 - 2658. [Abstract] [Full Text] [PDF]

				F. R. Khuri, J. J. Lee, S. M. Lippman, E. S. Kim, J. S. Cooper, S. E. Benner, R. Winn, T. F. Pajak, B. Williams, G. Shenouda, et al. Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer Patients. J Natl Cancer Inst, April 5, 2006; 98(7): 441 - 450. [Abstract] [Full Text] [PDF]

				B. Cartmel, D. Bowen, D. Ross, E. Johnson, and S. T. Mayne A Randomized Trial of an Intervention to Increase Fruit and Vegetable Intake in Curatively Treated Patients with Early-Stage Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2848 - 2854. [Abstract] [Full Text] [PDF]

				E. R. Gritz, C. Dresler, and L. Sarna Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2287 - 2293. [Abstract] [Full Text] [PDF]

				C. F. Perry, M. Stevens, I. Rabie, M.-E. Yarker, J. Cochrane, E. Perry, R. Traficante, and W. Coman Chemoprevention of Head and Neck Cancer With Retinoids: A Negative Result Arch Otolaryngol Head Neck Surg, March 1, 2005; 131(3): 198 - 203. [Abstract] [Full Text] [PDF]

				C. Lerman, F. Patterson, and W. Berrettini Treating Tobacco Dependence: State of the Science and New Directions J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323. [Abstract] [Full Text] [PDF]

				X. Wu, H. Zhao, K.-A. Do, M. M. Johnson, Q. Dong, W. K. Hong, and M. R. Spitz Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer Clin. Cancer Res., June 15, 2004; 10(12): 3988 - 3995. [Abstract] [Full Text] [PDF]

				J. C. Rhee, F. R. Khuri, and D. M. Shin Advances in Chemoprevention of Head and Neck Cancer Oncologist, June 1, 2004; 9(3): 302 - 311. [Abstract] [Full Text] [PDF]

				A. Argiris, B. E. Brockstein, D. J. Haraf, K. M. Stenson, B. B. Mittal, M. S. Kies, F. R. Rosen, B. Jovanovic, and E. E. Vokes Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy Clin. Cancer Res., March 15, 2004; 10(6): 1956 - 1962. [Abstract] [Full Text] [PDF]

				Y. I. Garces and J. T. Hays Tobacco Dependence: Why Should an Oncologist Care? J. Clin. Oncol., May 1, 2003; 21(9): 1884 - 1886. [Full Text] [PDF]

				N. L. Kobrinsky, M. G. Klug, P. J. Hokanson, D. E. Sjolander, and L. Burd Impact of Smoking on Cancer Stage at Diagnosis J. Clin. Oncol., March 1, 2003; 21(5): 907 - 913. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]

				M. P. Tabor, R. H. Brakenhoff, H. J. Ruijter-Schippers, J. E. van der Wal, G. B. Snow, C. R. Leemans, and B. J. M. Braakhuis Multiple Head and Neck Tumors Frequently Originate from a Single Preneoplastic Lesion Am. J. Pathol., September 1, 2002; 161(3): 1051 - 1060. [Abstract] [Full Text] [PDF]